Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans Acquires 10,000 Shares

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average price of $4.29 per share, with a total value of $42,900.00. Following the transaction, the chief financial officer now directly owns 150,900 shares in the company, valued at $647,361. This represents a 7.10 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Daron Evans also recently made the following trade(s):

• On Thursday, December 12th, Daron Evans bought 9,000 shares of Rezolute stock. The shares were acquired at an average cost of $4.60 per share, with a total value of $41,400.00.

Rezolute Price Performance

Shares of Rezolute stock opened at $4.39 on Friday. The stock has a market capitalization of $254.37 million, a P/E ratio of -3.46 and a beta of 1.01. The business’s 50 day simple moving average is $5.12 and its two-hundred day simple moving average is $4.78. Rezolute, Inc. has a one year low of $0.86 and a one year high of $6.19.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). Sell-side analysts expect that Rezolute, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rezolute

A number of institutional investors have recently made changes to their positions in RZLT. Jeppson Wealth Management LLC purchased a new stake in Rezolute during the second quarter valued at approximately $45,000. MML Investors Services LLC bought a new position in Rezolute during the 3rd quarter valued at about $57,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Rezolute in the third quarter worth $65,000. Virtu Financial LLC boosted its position in Rezolute by 58.0% in the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock valued at $126,000 after buying an additional 9,551 shares during the period. Finally, XTX Topco Ltd increased its holdings in Rezolute by 205.8% during the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares during the period. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. BTIG Research upped their price target on Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Guggenheim initiated coverage on shares of Rezolute in a research note on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Rezolute in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a research note on Friday, September 20th. Finally, Wedbush reiterated an “outperform” rating and set a $112.00 price target on shares of Rezolute in a research report on Monday, November 4th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $24.13.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.